Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Spatial Distribution of Invasive Pneumococcal Serotypes in West Africa: A Retrospective Analysis to Inform Immunization in Persons with Sickle Cell Disease

Thomas Carsillo, PhD, Kokou Hefoume Amegan-Aho, MD, Andrea Feller, PhD, Avery McIntosh, PhD, Jonathan Spector, MD MPH, Stephen K. Obaro, MD PhD

Blood (2018) 132 (Supplement 1): 3668.

https://doi.org/10.1182/blood-2018-99-119406

Published: 2018

Journal Articles

How Do New Immigrant Families (African Continent) with a Child with Sickle Cell Disease (SCD) Experience the Western Medical System?

Aisha Aiko Bruce, BA, MD FRCPC, Adrienne D. Witol, Psy.D., R.Psych, Haley Greenslade, BA, BSW, RSW, Mandeep Plaha, BSc Pharm, Mary Anne Venner, MSN, NP

Blood (2016) 128 (22): 3529.

https://doi.org/10.1182/blood.V128.22.3529.3529

Published: 2016

Journal Articles

Cell Of Origin Does Not Affect Outcomes In Early Stage Non-Bulky Diffuse Large B-Cell Lymphoma Treated With Short-Course Combined Modality Therapy

Matthew A. Lunning, DO, Jocelyn C. Maragulia, BS, Anita Kumar, MD, Martin Bast, BS, Philip Bierman, MD, R. Gregory Bociek, MD, Julie M Vose, MD, MBA, James O. Armitage, MD, Steven M. Horwitz, MD, Andrew D Zelenetz, MD, PhD

Blood (2013) 122 (21): 3017.

https://doi.org/10.1182/blood.V122.21.3017.3017

Published: 2013

Journal Articles

Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.

Shaji Kumar, Ian W. Flinn, Parameswaran N. Hari, Natalie Callander, Stephen J. Noga, A. Keith Stewart, Jonathan Glass, Noopur Raje, Robert M. Rifkin, Hongliang Shi, Iain J. Webb, Paul G. Richardson, S. Vincent Rajkumar

Blood (2009) 114 (22): 127.

https://doi.org/10.1182/blood.V114.22.127.127

Published: 2009

Journal Articles

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

Shaji Kumar, MD, Ian W Flinn, MD, PhD, Stephen J. Noga, MD, PhD, Parameswaran Hari, MD, MS, Robert M. Rifkin, MD, Natalie Scott Callander, MD, Manish Bhandari, MD, Jeffrey Lee Wolf, MD, Cristina Gasparetto, MD, Amrita Krishnan, MD, FACP, Daren D Grosman, MD, PhD, Jonathan Glass, MD, Entezam Asim Sahovic, MD, Hongliang Shi, MS, Iain J. Webb, MD, Paul Richardson, MD, S. Vincent Rajkumar, MD

Blood (2008) 112 (11): 93.

https://doi.org/10.1182/blood.V112.11.93.93

Published: 2008

Journal Articles

Intensive Versus Double Intensive Therapy in Untreated Multiple Myeloma: Final Analysis of the HOVON 24 Trial.

Pieter Sonneveld, MD, Bronno van der Holt, MSc, Edo Vellenga, MD, Sandra Croockewit, MD, Gregor Verhoef, MD, Christine Segeren, MD, Henk Lokhorst, MD

Blood (2005) 106 (11): 2545.

https://doi.org/10.1182/blood.V106.11.2545.2545

Published: 2005

NARROW

Spatial Distribution of Invasive Pneumococcal Serotypes in West Africa: A Retrospective Analysis to Inform Immunization in Persons with Sickle Cell Disease

How Do New Immigrant Families (African Continent) with a Child with Sickle Cell Disease (SCD) Experience the Western Medical System?

Cell Of Origin Does Not Affect Outcomes In Early Stage Non-Bulky Diffuse Large B-Cell Lymphoma Treated With Short-Course Combined Modality Therapy

Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

Intensive Versus Double Intensive Therapy in Untreated Multiple Myeloma: Final Analysis of the HOVON 24 Trial.

Email alerts

ASH Publications

American Society of Hematology

Spatial Distribution of Invasive Pneumococcal Serotypes in West Africa: A Retrospective Analysis to Inform Immunization in Persons with Sickle Cell Disease

How Do New Immigrant Families (African Continent) with a Child with Sickle Cell Disease (SCD) Experience the Western Medical System?

Cell Of Origin Does Not Affect Outcomes In Early Stage Non-Bulky Diffuse Large B-Cell Lymphoma Treated With Short-Course Combined Modality Therapy

Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

Intensive Versus Double Intensive Therapy in Untreated Multiple Myeloma: Final Analysis of the HOVON 24 Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only